期刊文献+

应用高效液相色谱检测仪对他克莫司滴眼液的含量测定检测

Determination of Tacrolimus Eye Drops by HPLC
下载PDF
导出
摘要 目的:建立测定他克莫司滴眼液含量的高效液相色谱法。方法:以高效液相色谱法(HPLC)测定他克莫司含量,Agilent SB-CN柱为色谱柱;流动相乙腈:0.1磷酸=35:65(V/V),柱温40℃,流速2mL/min,紫外检测波长210nm。结果:在0.0248~0.2480mg/mL范围内(r=0.9997),他克莫司峰面积和质量浓度呈良好线性关系,平均回收率为99.0%,RSD为0.79%。3批他克莫司滴眼液含量分别为99.3%、99.6%、100.1%。结论:该含量测定方法准确度高,操作简便,检测结果具有较高稳定性,专属性强,在制剂质量控制中有明显效果。 Objective:To establish a HPLC method for the determination of tacrolimus eye drops.Methods:The content of tacrolimus was determined by HPLC with Agilent sb-cn as the column,acetonitrile as the mobile phase:0.1 phosphoric acid=35:65(V/V),column temperature 40℃,flow rate 2 m L/min,UV detection wavelength 210 nm.Results:In the range of 0.0248~0.2480 mg/m L(r=0.9997),there was a good linear relationship between the peak area of tacrolimus and the mass concentration,with an average recovery of 99.0%and RSD of 0.79%.The contents of three batches of tacrolimus eye drops were 99.3%,99.6%and 100.1%respectively.Conclusion:The method has high accuracy,simple operation,high stability and specificity,and has obvious effect in the quality control of preparations.
作者 陈宇翔 王娟 魏宗有 陈忠 陈韡彬 江宁宇 CHEN Yu-xiang;WANG Juan;WEI Zong-you;CHEN Zhong;CHEN Wei-bin;JIANG Ning-yu(Fujian Institute of Microbiology,Fujian Fuzhou 350007)
出处 《中国医疗器械信息》 2020年第3期14-14,106,共2页 China Medical Device Information
关键词 他克莫司滴眼液 高效液相色谱法 含量测定 tacrolimus eye drops HPLC content determination
  • 相关文献

参考文献6

二级参考文献27

  • 1周清,陈剑,张静辉,杨水平,陈敏,陈琳.安贺拉滴眼液治疗干眼的实验研究[J].热带医学杂志,2007,7(6):543-545. 被引量:1
  • 2Gerber DA,Bonham CA,Thomso AW.Immunosuppressive agent:recent developments in molecular action and clinical application[J].Transplatation Proceedings,1998,30:1573.
  • 3Spencer CM,Goa KL,Gillis JC,et al.Tacrolimus.an update of its pharmacology and clinical efficacy in the management of organ transplantation[J].Drugs,1997,54:925.
  • 4Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease[ J ]. Ophthalmology ,2005,112( 8 ) : 1472-1477.
  • 5Baker KB, Spurrier N J, Watkins AS, et al. Retention time h~r corticosleroid-sparing systemic immunosuppressive agents in patients with inflammalory eye disease[ J ]. Br J Ophthahnol, 2006,90 ( 12 ) : 1481 - 1485. doi: 10. 1156/bjo. 2006. 097998.
  • 6Galor A, Thorrle JE. Seleritis and peripheral ulcerative keratitis [ J ]. Rheum Dis Clin North Am,2007,33 (4) : 835-854. doi: 10. 1016/j. rdc. 2007.08. 002.
  • 7Messmer EM, Foster CS. Yasculitic peripheral ulcerative keratitis [ J ]. Surv Ophthalmol, 1999,43 ( 5 ) : 379-396.
  • 8Yagei A. Update on peripheral ulcerative keratitis [ J ]. Clin Ophthalmol,2012,6 : 747-754. doi : 10. 2147/OPTH. $24947.
  • 9Tung TH. Tacrolimus ( FK506 ) : Safety and Applications in Reconstructive Surgery[J]. Hand (N Y) ,2010,5 (1) : 1-8. doi: 10. 1007/s11552-009- 9193-8.
  • 10Hoekstra HJ,Hawkins K,de Boer WJ,et al. Gastrointestinal complications in lung transplant survivors that require surgical intervention [ J ]. Br J Surg,2001,88(3) :433-438. doi:10. 1046/j. 1365-2168. 2001. 01693. x.

共引文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部